References
- Reddy N, Abel T W, Jagasia M, Morgan D, Weaver K, Greer J. Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab. Leuk Lymphoma 2009; 50: 460–462
- Hopfinger G, Plessl A, Grisold W, Klimpfinger M, Hoftberger R, Reinhart B, et al. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4 lymphocyte count. Leuk Lymphoma 2008; 49: 2367–2369
- Carson K R, Evens A M, Gordon L I, Seymour J F, Rosen S T, Gottardi-Littell N, et al. Rituximab and progressive multifocal leukoencephalopathy: a report of 35 cases. J Clin Oncol (Suppl) 2008; 26: 8531, (Abstract)
- Genentech. Rituxan website. 2009, Accessed at http://www.rituxan.com
- Gribben J G. How I treat indolent lymphoma. Blood 2007; 109: 4617–4626
- Engsig F N, Hansen A B, Omland L H, Kronborg G, Gerstoft J, Laursen A L, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2008; 199: 77–83
- Bouaziz J D, Yanaba K, Venturi G M, Wang Y, Tisch R M, Poe J C, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007; 104: 20878–20883